|
ZNF322A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.01999999954938E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.35769999999969E-05 |
| Normal-vs-Stage2 |
7.227900E-04 |
| Normal-vs-Stage3 |
3.19189999986591E-07 |
| Normal-vs-Stage4 |
1.93649999999934E-05 |
| Stage1-vs-Stage2 |
9.892800E-01 |
| Stage1-vs-Stage3 |
1.339960E-01 |
| Stage1-vs-Stage4 |
1.414000E-01 |
| Stage2-vs-Stage3 |
2.781000E-01 |
| Stage2-vs-Stage4 |
2.316400E-01 |
| Stage3-vs-Stage4 |
7.233600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.91569999974384E-07 |
| Normal-vs-AfricanAmerican |
1.479900E-02 |
| Normal-vs-Asian |
3.816300E-04 |
| Caucasian-vs-AfricanAmerican |
4.808600E-01 |
| Caucasian-vs-Asian |
6.094200E-01 |
| AfricanAmerican-vs-Asian |
7.613400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.818560E-04 |
| Normal-vs-Female |
2.26040000050887E-07 |
| Male-vs-Female |
1.608960E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.57999999999792E-05 |
| Normal-vs-Age(41-60Yrs) |
3.12049999950936E-07 |
| Normal-vs-Age(61-80Yrs) |
1.8804599999922E-05 |
| Normal-vs-Age(81-100Yrs) |
5.003700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.454400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.832200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.808400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.004600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.543200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.978000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.69470000002769E-06 |
| Classical-VS-Follicular |
5.066400E-01 |
| Classical-VS-Other |
5.346600E-01 |
| Classical-VS-Normal |
4.12189999999812E-05 |
| Tall-VS-Follicular |
4.977400E-04 |
| Tall-VS-Other |
2.982800E-01 |
| Tall-VS-Normal |
6.38419983545191E-10 |
| Follicular-VS-Other |
7.227600E-01 |
| Follicular-VS-Normal |
2.550400E-04 |
| Other-VS-Normal |
4.485600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.78744999999036E-05 |
| Normal-vs-N1 |
2.481400E-03 |
| N0-vs-N1 |
7.912400E-01 |
|
|
